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SObjective: The objective of this analysis was to develop a survival aggregate score (SAS), including
objective and subjective patient-based parameters, and assess its prognostic role after major anatomic resection
for non–small cell lung cancer.
Methods: A total of 245 patients underwent major lung resections for non–small cell lung cancer with preop-
erative evaluation of quality of life (Short-Form 36v2 survey) and complete follow-up. The Cox multivariable
regression and bootstrap analyses were used to identify prognostic factors of overall servival, which were
weighted to construct the scoring system and summed to generate the SAS.
Results: Cox regression analysis showed that the factors negatively associated with overall survival and used to
construct the score were 36-item short-form health survey physical component summary score less than 50 (haz-
ard ratio [HR], 1.7; P¼ .008), aged older than 70 years (HR, 1.9; P¼ .002), and carbon monoxide lung diffusion
capacity less than 70% (HR, 1.7; P¼ .01). Patients were grouped into 4 risk classes according to their SAS. The
5-year overall survival was 78% in class SAS0, 59% in class SAS1, 42% in class SAS2, and 14% in class SAS3
(log-rank test, P< .0001). SAS maintained its association with overall survival in patients with stages pT1
(log-rank test, P¼ .01), pT2 (log-rank test, P¼ .02), or pT3-4 (log-rank test, P¼ .001), and in those with stages
pN0 (log-rank test, P¼ .0005) or pN1-2 (log-rank test, P¼ .02). The 5-year cancer-specific survival was 83% in
class SAS0, 71% in class SAS1, 63% in class SAS2, and 17% in class SAS3 (log-rank test, P<.0001).
Conclusions: This system may be used to refine stratification of prognosis for clinical and research purposes.
(J Thorac Cardiovasc Surg 2013;146:385-90)Supplemental material is available online.
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Objective measures of performance1-3 and patient-
perceived physical status4-6 have been associated with
survival time after surgery in patients with non–small cell
lung cancer (NSCLC).
The objective of this study was to develop an aggregate
scoring system, incorporating objective and subjective
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The Journal of Thoracic and Cawith prognosis in patients undergoing curative anatomic
resection for NSCLC.METHODS
This is a prospective longitudinal study on 407 patients who underwent
lobectomy or pneumonectomy and systematic nodal dissection for NSCLC
from January 2004 to December 2008. The stages of patients were deter-
mined according to the American Joint Committee on Cancer guidelines.7
A total of 311 patients underwent preoperative assessment of quality of
life (QoL). Sixty-six of them were lost to follow-up. The remaining 245
patients (214 lobectomies and 31 pneumonectomies) were analyzed. A pre-
liminary analysis showed that the patients with preoperative QoL assess-
ment (included in the study) had similar overall 5-year survival (55% vs
56%; log-rank test, P ¼ .9) compared with those without QoL assessment
(excluded from the study).
This study was approved by the hospital Institutional Review Board, and
all patients gave their informed consent to use their clinical data for scien-
tific purposes. Operability exclusion criteria included a predicted postoper-
ative forced expiratory volume in 1 second (FEV1) and a predicted
postoperative DLCO lower than 30%, in addition to an oxygen consump-
tion per unit time peak lower than 10 mL/kg per minute. As a rule, opera-
tions were performed through a lateral muscle- and nerve-sparing
thoracotomy by Board-certified thoracic surgeons.
Patients were extubated in the operating room and transferred to a ded-
icated thoracic ward. Postoperative management focused on early mobili-
zation, antithrombotic and antibiotic prophylaxis, and physical and
respiratory rehabilitation. Thoracotomy chest pain was assessed at least
twice daily and controlled through a systemic, continuous infusion of non-
opioid drugs. Therapy was titrated to achieve a visual analogue score lower
than 5 (scale range, 0-10) during the first 48 to 72 hours. No formalrdiovascular Surgery c Volume 146, Number 2 385
Abbreviations and Acronyms
CI ¼ confidence interval
DLCO ¼ carbon monoxide lung diffusion capacity
ECOG ¼ Eastern Cooperative Oncology group
FEV1 ¼ forced expiratory volume in 1 second
FVC ¼ forced vital capacity
HR ¼ hazard ratio
LTFU ¼ lost to follow-up
MCS ¼ mental component summary
NSCLC ¼ non–small cell lung cancer
PCS ¼ physical component summary
QoL ¼ quality of life
SAS ¼ survival aggregate score
SF36 ¼ 36-item short-form health survey
SF36v2 ¼ Short-Form 36v2
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S preadmission or postdischarge physiotherapy or psychological supportive
programs were administered.
Neurological or psychotropic personal medications, if present, were
generally resumed the day after surgery.
QoL Assessment
QoL was assessed before the operation by the administration of the
Short-Form 36v2 (SF36v2) survey. The SF36v2 questionnaire8 is a generic
instrument assessing 8 health physical and mental concepts (physical func-
tioning, role limitation caused by physical problems, bodily pain, general
health perception, vitality, social functioning, role limitation caused by
emotional problems, and mental health). Scores were standardized to
norms, and their weighted averages were used to create physical compo-
nent summary (PCS) and mental component summary (MCS) scores on
a standard scale. Norm-based scores have a mean of 50 and an SD of 10.
As a consequence, for all health dimensions and component scales, any
score lower than 50 is lower than the general population mean and each
point represents one tenth of an SD. This allows for a direct comparison
of measures among different populations and scales.
Survival
Follow-up was obtained by routine office visits, telephone contact, or
data retrieved from the Regional Health Care System database. All patients
were observed through April 2011. The cause of death was recorded based
on physician report, ascertaining death for those cases retrieved from the
Regional Health Care System database or reported by family members
when telephone contact was used. The median follow-up calculated by
using the reverse Kaplan-Meier method was 37 months. Perioperative
mortality occurred in 3 patients in this series, and these events were counted
as overall deaths and included in the survival analysis.
Statistical Analysis
The following baseline and tumor variables were tested for a possible
association with survival: age, sex, body mass index, American Society
of Anesthesiologist score, Eastern Cooperative Oncology group (ECOG)
score, FEV1 percentage, carbon monoxide lung diffusion capacity
(DLCO percentage), FEV1/forced vital capacity (FVC) ratio, history of
coronary artery disease, renal insufficiency (creatinine level>2 mg/dL),
preoperative hemoglobin level, histology (adenocarcinoma vs squamous,
vs others), induction chemotherapy, and SF36v2 PCS and MCS QoL
scales. For this study, PCS and MCS were categorized according to their
values higher or lower than 50 (general population norms). Survival was386 The Journal of Thoracic and Cardiovascular Surgdefined as the interval between surgery to death or last contact. Patients
who were not reported as dead at the time of the analysis were censored
at the date they were last known to be alive.
Survival distribution was estimated by the Kaplan-Meier method.
Significant differences in probability of surviving between the strata
were evaluated by log-rank test.
Cox multivariable proportional hazards regression analysis was used to
evaluate the effects of prognostic factors on survival. Predictors with P<.1
at univariable analysis (univariable Cox regression analysis for numeric
variables and log-rank test for categorical variables) were used in the mul-
tivariable model.
Only 1 variable in a set of variables with a correlation coefficient greater
than 0.5 was selected (by bootstrap procedure) and used in the regression
model to avoid multicollinearity.
For the purpose of constructing the aggregate score, numeric variables
were tested for a threshold effect and dichotomized by using receiver oper-
ating characteristic (curve) analysis (for identifying the best cutoff).
Bootstrap bagging with 1000 samples was used to assess the stability of
the multivariable regression analysis predictors. In the bootstrap analysis,
1000 samples of the same size as the original population were drawn,
with replacement from the original data set. ACox proportional hazards re-
gression model was repeated in each of these samples. If the final model
variables occurred in most (>50%) of the bootstrap models, the original
final regression model can be judged to be stable.9 Only those variables
with P<.1 and a bootstrap frequency of greater than 50% were retained
in the final model and used to construct the score.
Construction of the Survival Aggregate Score
The scoring system was developed by proportional weighing of the
significant predictor estimates, assigning a value of 1 to the smallest coef-
ficient. An aggregate risk score was generated for each patient by summing
each estimate. Finally, patients were grouped in classes of incremental risk
according to their total score.
The stability of the risk score across multiple populations was further
tested in 1000 bootstrapped samples drawnwith replacement from the orig-
inal data set.
A significance level of .05 was chosen to assess the statistical signifi-
cance. All tests were performed on Stata 9.0 statistical software (Stata
Corporation, College Station, Tex).
RESULTS
The characteristics of the patients included in this study
are shown in Table 1.
The 5-year and median overall survival levels in the
entire population were 55% and 75 months, respectively.
The following variables were associated with overall sur-
vival at univariable analysis and were used as independent
predictors in the Cox proportional hazards regression anal-
ysis: age (P ¼ .008), FEV1 percentage (P ¼ .04), FEV1/
FVC ratio (P ¼ .04), DLCO percentage (P ¼ .02), ECOG
score (P ¼ .01), and PCS less than 50 (P ¼ .006).
To construct the aggregate score, receiver operating char-
acteristic (curve) analysis was used to categorize the nu-
meric variables. The following best thresholds were
found: aged older than 70 years (c index, 0.58), FEV1 lower
than 80% (c index, 0.55), FEV1/FVC less than 0.7 (c index,
0.58), DLCO less than 70% (c index, 0.58), and ECOG
score greater than 2 (c index, 0.63).
Cox proportional hazards regression analysis showed that
the factors negatively associated with overall survival in theery c August 2013
TABLE 1. Characteristics of the 245 patients included in the study
Variables Value
Age, y 67 (9.7)
Aged>70 y* 114 (47)
FEV1,% 84.6 (19.3)
DLCO,% 77.3 (18.8)
Male sex* 198 (81)
Coronary artery disease* 32 (13)
ASA 2.3 (0.5)
ECOG 0.7 (0.7)
PCS 50.9 (7.8)
MCS 46.6 (12.7)
Pneumonectomy* 31 (13)
Histology* Adenocarcinoma 131 (53)
Squamous 78 (32)
Others 37 (15)
pT stagey 1 104
2 123
>2 18
pN stagey 0 180
1 31
2 34
Results are reported as means (SDs) unless otherwise specified. FEV1, Forced expi-
ratory volume in 1 second; DLCO, carbon monoxide lung diffusion capacity; ASA,
American Society of Anesthesiologist; ECOG, Eastern Cooperative Oncology group;
PCS, physical component score; MCS, mental component score. *Data are given as
number (percentage). yData are given as number of patients.
FIGURE 1. Kaplan-Meier estimates of overall survival in all patients with
non–small cell lung cancer, according to different survival aggregate scores
(log-rank test, P<.0001). SAS, Survival aggregate score.
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Sentire series were PCS less than 50 (coefficient, 0.55; haz-
ard ratio [HR], 1.7; 95% confidence interval [CI], 1.2-2-
6; P ¼ .008; bootstrap frequency, 78%), aged older than
70 years (coefficient, 0.64; HR, 1.9; 95% CI, 1.3-2.9;
P ¼ .002; bootstrap frequency, 86%), and DLCO less
than 70% (coefficient, 0.55; HR, 1.7; 95% CI, 1.1-2.6;
P ¼ .01; bootstrap frequency, 72%). Performance of the
model was as follows: log likelihood, 463.3; log-rank
c2, 22.2 (P ¼ .0001); and goodness of fit for the inclusion
of design variables based on 2 quartiles of risk, P ¼ .9.
Basedon their regression coefficients of similarmagnitude,
a weighted score was created, assigning 1 point to all factors.
Points were summed, obtaining a cumulative aggregate
score for each patient ranging from 0 to 3. For instance, a pa-
tient older than 70 years with a PCS score lower than 50 and
a DLCO less than 70% would have a score of 3.
Patients were then grouped into 4 risk classes according to
their aggregate score,whichwas significantly associatedwith
incremental risk of death: class survival aggregate score
(SAS) 0, 0 points (n¼ 56); class SAS1, 1 point (n¼ 98); class
SAS2, 2 points (n ¼ 75); and class SAS3, 3 points (n¼ 16).
Figure 1 shows theKaplan-Meier estimates of overall sur-
vival according to different SASs (log-rank test, P<.0001).
The 5-year andmedian overall survival levels in the 4 groups
were as follows: class SAS0, 78% and median survival
not reached; class SAS1, 59% and median survival not
reached; class SAS2, 42% and 47 months; and class
SAS3, 14% and 15 months. The median survival is theThe Journal of Thoracic and Catime at which half the subjects have reached the event of in-
terest. If the survival curve does not fall to 0.5 (50%), then
the median time cannot be computed. All log-rank pairwise
comparisons between different SAS levels yielded P<.05.
Bootstrap bagging showed that the SAS was significantly
associated with overall survival (log-rank test, P<.05) in
98% of 1000 simulated populations drawn with replace-
ment from the original data set.
SAS was associated with overall survival in all pT stages
(Table 2 and Figures E1 and E2). Limited to patients with
pT1 and pT2 stages, SAS was associated with overall
survival in patients with both pN0 and pN1-2 stages
(Table 3 and Figures E3 and E4).
In pT1 N0 patients, the 5-year overall survival rates were
92% in SAS0, 65% in SAS1, 36% in SAS2, and 25% in
SAS3 (log-rank test, P ¼ .003; Figure E5).
Similarly, in pT2 N0 patients, the 5-year overall survival
rates were 86% in class SAS0, 66% in class SAS1, 50% in
class SAS2, and 0% in class SAS3 (log-rank test, P ¼ .1
Figure E6).
Figure 2 shows the Kaplan-Meier estimates of cancer-
specific survival according to SAS (log-rank test,
P<.0001). The 5-year and median cancer-specific survival
levels in the 4 groups were as follows: class SAS0, 83% and
median survival not reached; class SAS1, 71% and median
survival not reached; class SAS2, 63% and median survival
not reached; and class SAS3, 17% and 20 months.DISCUSSION
Rationale and Objective
Patient-centered factors are increasingly reported to be as-
sociated with long-term survival in patients with cancer,10,11
including lung cancer surgical patients.1-6 Although their
causal link with survival remains speculative, they can be
used to refine prognostic stratification.rdiovascular Surgery c Volume 146, Number 2 387
TABLE 2. Median and 5-year overall survival of patients with different pT stages according to their SAS
pT stage
SAS0 SAS1 SAS2 SAS3 Log-rank
P valueMedian, mo 5 y,% Median, mo 5 y,% Median, mo 5 y,% Median, mo 5 y,%
1 nr 80 75 59 53 39 20 20 .01
2 nr 82 nr 61 38 45 16 0 .02
3-4 23 50 nr 57 17 25 5 0 .001
SAS, Survival aggregate score; nr, not reached.
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subjective nononcologic factors associated with survival af-
ter anatomic lung resection for NSCLC and to incorporate
them into a single aggregate score.
Main Finding
An age older than 70 years at operation, a preoperative
DLCO lower than 70% predicted, and a preoperative QoL
PCS score lower than the norm of the general population
were associated with worse overall survival. These 3 factors
were used to construct a score ranging from 0 to 3 points
(where 0 corresponds to 0 of the factors present and 3 cor-
responds to all 3 factors present). Patients with a score of
0 had a 5-year overall survival that was almost 6-fold longer
than those with a score of 3. The score remained associated
with overall survival even when the patients were stratified
by pT and pN stages and was also associated with cancer-
specific survival.
Evidence Context
Several retrospective series have reported on the associa-
tion of age and prognosis in patients with NSCLC. In gen-
eral, most of the studies support that surgery of early-stage
NSCLC in elderly persons is feasible and yields similar
survival benefits compared with younger patients.12 Two re-
cent analyses from the national Surveillance, Epidemiol-
ogy, and End Results database found somewhat different
results. In a population of approximately 15,000 patients,
Owonikoko and colleagues13 found that elderly persons
had worse overall survival, independent of sex, stage, and
histology. However, in the surgical group, they did not ob-
serve any survival differences between elderly and younger
patients. Sigel and colleagues14 found that among resected
male patients, 5-year relative survival rates declined with
advanced age.
In our study, an age older than 70 years significantly as-
sociated with worse overall survival. This may be partly ex-
plained by the highest incidence of competing risks inTABLE 3. Median and 5-year overall survival of patients with pT1 and pT
pN stage
SAS0 SAS1
Median, mo 5 y,% Median, mo 5 y,%
0 nr 88 nr 66
1-2 nr 57 nr 51
SAS, Survival aggregate score; nr, not reached.
388 The Journal of Thoracic and Cardiovascular Surgelderly patients, who are more likely to have an increased
burden of comorbidities and limited life expectancy, con-
firming previous reports.15,16
Preoperative carbon monoxide lung diffusion capacity
has previously been a predictor of overall1 and cause-spe-
cific2 long-term survival. Ferguson and colleagues1 found
that DLCO was a predictor of overall survival and that
a value of 80% was the best cutoff to identify patients at in-
creased risk of mortality. This value was similar to the cut-
off found in our analysis.
There is a growing body of evidence showing the associ-
ation between health-related QoL data and survival in pa-
tients with cancer.10 Although self-reported health status
has been the focus of many studies in patients with advanced
lung cancer stages, limited information exists about the in-
fluence of baseline QoL measures on long-term survival in
patients with early-stage NSCLC who underwent surgery.
M€oller and Sartipy4 and Pompili and colleagues6 found
that the 36-item short-form health survey (SF36) PCS score
was a significant independent predictor of survival after sur-
gery. Sloan and colleagues5 analyzed amixed series, includ-
ing both surgical and nonsurgical patients, using the Lung
Cancer Symptom Scale. They found that an overall QoL
score lower than 50 was associated with poor prognosis.
In the present analysis, a PCS lower than the normal
values of the general population was associated with shorter
survival time after adjusting for other prognostic factors.
Nevertheless, the association between self-rated health
and mortality should not be inferred as a causal relationship.
The PCS score may be interpreted as a parameter reflecting
other unknown or unrecorded biological factors relevant to
survival.11
Another hypothesis may refer to the concept of interocep-
tion, the individual’s superior ability to sense and incorporate
even nonconceptualized sensations of bodily status into
self-ratings of health through the conscious representation of
humoral and biochemical signals.17,18 This may contribute
to the association of self-rated health with mortality.192 stages with negative or positive lymph nodes according to their SAS
SAS2 SAS3 Log-rank
P valueMedian, mo 5 y,% Median, mo 5 y,%
59 45 32 23 .0005
36 40 12 0 .02
ery c August 2013
FIGURE 2. Kaplan-Meier estimates of cancer-specific survival in all pa-
tients, according to different survival aggregate scores (log-rank test,
P<.0001). SAS, Survival aggregate score.
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SCaveats and Limitations
The study included patients undergoing major anatomic
pulmonary resections performed through a muscle-sparing
lateral thoracotomy. The prognostic relevance of SAS in
other types of resections or surgical accesses (ie, video-
assisted thoracic surgery) needs to be confirmed.
We considered only preoperative variables. Perioperative
changes may also have an influence on survival.4 However,
postoperative changes of QoL and DLCO may reflect other
treatment- and cancer-related factors, and their relation-
ships with prognosis deserve specific investigations.
The SF36v2 scaleswere used tomeasureQoL because this
was the questionnaire in use during the period of the study.
More cancer-specific instruments (ie, EuropeanOrganization
for Research and Treatment of Cancer Quality of Life
Questionnaire-30/Lung Cancer 13) may yield different re-
sults and contribute to find additional information.
Approximately 20% of the patients initially eligible for
the study were lost to follow-up (LTFU). This may be, in
part, explained by the absence of a centralized institutional
follow-up system and the broad catchment area. We as-
sessed the potential impact of this dropout rate on the results
using 2 extreme approaches. When all LTFU patients were
assumed as dead, the log-rank test for overall survival
yielded a c2 value of 14.3, with P ¼ .002. When all
LTFU patients were assumed as alive, the log-rank test for
overall survival yielded a c2 value of 22.8, with
P < .0001. Based on this simulation, we can conclude
with a certain degree of reliability that the inclusion of
lost patients would have not influenced the results.
This analysis has been limited to patients who were able
to complete the preoperative QoL questionnaire and to per-
form the preoperative exercise test. Patients unable or un-
willing to do so may have specific baseline, medical, or
psychosocial characteristics that deserve to be evaluated
separately to verify their association with prognosis.The Journal of Thoracic and CaA larger sample size will be needed to refine and improve
discrimination of the model among the highest-risk group.
In fact, in our analysis, a 71-year-old patient with
a DLCO of 65% and an SF36 PCS of 45 has the same
SAS as an 88-year-old patient with a DLCO of 40% and
an SF36 PCS of 35. This may limit the ability of this scoring
system to be used as a risk-adjustment instrument in clinical
trials.Clinical and Research Implications
The discriminative ability of SAS can be used to refine
prognostic stratification in patients with NSCLC who un-
derwent lung resection for either clinical or research
purposes.
Patients with a high SAS can be identified and counseled
for more frequent follow-up, regardless of their pTNM
stage.
Supportive pharmacologic or rehabilitative measures can
be established to increase the levels of DLCO or QoL PCS
score, with the objective to potentially improve prognosis.
In this regard, several studies have shown the beneficial
effects of physical function on cancer recurrence mediated
by a reduction in body weight and composition and changes
in metabolic and sex hormones, growth factors, adipokines,
immune function, or inflammation.20-22 Therefore, the
implementation of preoperative rehabilitation programs
capable of improving the aerobic capacity23-25 may
influence residual QoL and long-term survival.
With the limitation previously mentioned, SAS can be
used as a risk-adjustment instrument in clinical trials assess-
ing the efficacy of novel surgical techniques (ie, sublobar
resections in early-stage, minimally invasive thoracic sur-
gery) or adjuvant treatments (chemotherapy or biologic
agents).
Future investigations are needed to explore the feasibility
and efficacy of adjuvant treatment in patients with early-
stage NSCLC with a high SAS, which, as previously men-
tioned, may be a surrogate for a subclinical immunologic or
humoral substrate favoring cancer progression.11,19
SAS, which is a patient-centered model, may be inter-
preted as the initial step toward the construction of a more
complex model, including treatment- and cancer-related
prognostic factors. This cumulative model will require
a larger sample size analysis to be developed.CONCLUSIONS
In conclusion, we developed an aggregate score incorpo-
rating patient-based preoperative objective (DLCO and age)
and subjective (QoL PCS score) factors, which was associ-
ated with prognosis after lung resection for NSCLC.
Higher scores corresponding to worse patient conditions
are associated with poorer overall and cancer-specific
survival.rdiovascular Surgery c Volume 146, Number 2 389
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gations, this index may be used to refine stratification of
prognosis for clinical and research purposes.References
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FIGURE E1. Kaplan-Meier estimates of overall survival in patients with
pT1 stage non–small cell lung cancer, according to different survival aggre-
gate scores (log-rank test, P ¼ .01). SAS, Survival aggregate score.
FIGURE E2. Kaplan-Meier estimates of overall survival in patients with
pT2 stage non–small cell lung cancer, according to different survival aggre-
gate scores (log-rank test, P ¼ .02). SAS, Survival aggregate score.
FIGURE E3. Kaplan-Meier estimates of overall survival in patients with
pT1-2 N0 stage non–small cell lung cancer, according to different survival
aggregate scores (log-rank test, P¼ .0005). SAS, Survival aggregate score.
FIGURE E4. Kaplan-Meier estimates of overall survival in patients with
pT1-2 N1-2 stage non–small cell lung cancer, according to different sur-
vival aggregate scores (log-rank test, P ¼ .02). SAS, Survival aggregate
score.
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FIGURE E5. Kaplan-Meier estimates of overall survival in patients with
pT1 N0 stage non–small cell lung cancer, according to different survival
aggregate scores (log-rank test, P ¼ .04). SAS, Survival aggregate score.
FIGURE E6. Kaplan-Meier estimates of overall survival in patients with
pT2 N0 stage non–small cell lung cancer, according to different survival
aggregate scores (log-rank test, P ¼ .1). SAS, Survival aggregate score.
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